<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00460226</url>
  </required_header>
  <id_info>
    <org_study_id>LBI108245</org_study_id>
    <nct_id>NCT00460226</nct_id>
  </id_info>
  <brief_title>Lamictal Bipolar Observational Study</brief_title>
  <official_title>A Multi-centre, Observational Study to Evaluate the Incidence of Non-serious Rash in Korean Bipolar I Patients With Lamotrigine Therapy in Real World Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This is multi-center, prospective, observational stud. This study is designed to evaluate the
      rate of non-serious rash in Korean bipolar I patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of non-serious rash during 12 weeks of treatment with lamotrigine in patients with bipolar I in Korea</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>CGI-BP at Week 12 and occurrence of adverse events at Week 12</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">238</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>lamotrigine</arm_group_label>
    <description>there is only one group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lamotrigine</intervention_name>
    <description>lamotrigine treatment for 12weeks</description>
    <arm_group_label>lamotrigine</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient setting and reflecting usual clinical practice in general hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  A subject will be eligible for inclusion in this study only if all of the following
             criteria apply:

          -  Provides written informed consent

          -  Male or female age 18 years or older A female subject is eligible to enter and
             participate in the study if she is of;

          -  Non-childbearing potential

          -  Childbearing potential, has a negative pregnancy test at screen

          -  Diagnosis of bipolar I disorder using DSM-IV criteria

        Exclusion criteria:

          -  A subject will not be eligible for inclusion in this study if any of the following
             criteria apply:

          -  Previous or current treatment with lamotrigine

          -  Presence of a clinically significant psychiatric or physiologic comorbidity, including
             significant substance abuse, severe depression or mania which is of an unstable or
             progressive nature that could, in the opinion of the investigator, interfere with
             participation in this study

          -  Presence of untreated thyroid disease

          -  Have active suicidality or homicidality, history of recent suicide attempts within the
             past year, or, in the investigator's opinion, a marked risk for suicide

          -  History of severe hepatic or renal insufficiency or significant hematologic disease or
             other significant medical or psychiatric condition that would interfere with subjects'
             participation in the study

          -  Currently participating in another clinical trial, or plans to enroll in another trial
             while participating in this study

          -  Currently pregnant or is breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <reference>
    <citation>Woo YS, Bahk WM, Jon DI, Joo YH, Kim W, Seo JS, Ahn YM, Chung SK, Won SH, Shin YC, Yoon BH, Jung SH, Seok JH, Lee YS, Kim Y, Min KJ. Rash in adult patients receiving lamotrigine to treat bipolar I disorder in Korea: a multicenter, prospective, naturalistic, open-label trial. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Oct 1;33(7):1147-52. doi: 10.1016/j.pnpbp.2009.06.010. Epub 2009 Jun 18.</citation>
    <PMID>19540298</PMID>
  </reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2007</study_first_submitted>
  <study_first_submitted_qc>April 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2007</study_first_posted>
  <last_update_submitted>March 15, 2012</last_update_submitted>
  <last_update_submitted_qc>March 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Korean</keyword>
  <keyword>Bipolar I disorder</keyword>
  <keyword>Non-serious rash</keyword>
  <keyword>Lamotrigine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

